Merus (MRUS)
(Delayed Data from NSDQ)
$59.99 USD
+15.92 (36.12%)
Updated May 24, 2024 03:59 PM ET
After-Market: $60.44 +0.45 (0.75%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Merus N.V. [MRUS]
Reports for Purchase
Showing records 61 - 80 ( 173 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Objective Response and Tumor Regression in NRG1 Solid Tumors at ASCO
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
1Q21: Clinical Update from Lead Program at the ASCO Meeting in June
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Zeno Looks to Shine At ASCO 2021; Reit Buy and $30PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Merus? Fourth Clinical Asset (MCLA-129) Aims to Address Resistance in NSCLC and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Our Covered Companies at the 33rd ROTH Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
4Q20 - Clinical Update in 2021 for Lead Program
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
eNRGy Trial Aims to Supercharge Merus in 2Q21; Reit Buy and Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Patient Selection and Therapeutic Dose May be Key in Colorectal Cancer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Do Not Forget to Join Our Webinar with Management Today at 1 PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T